Abstract
The changes in beta-cell mass (BCM) during the course of diabetes are not yet well characterized. A non-invasive method to measure the BCM in vivo would allow us to study the BCM during the onset and progression of the diseases caused by beta-cell dysfunction. PET and SPECT imaging are attractive approaches to determine the BCM because of their high sensitivity and the possibility to quantitatively analyze the images. Several targets and their corresponding radiotracers have been examined for their ability to determine the BCM including radiolabeled antibodies, antibody fragments, peptides and small molecules. Although some of these tracers show promising results, there is still no reliable method to determine the beta-cell mass in vivo. In this review, the targets and the corresponding radiotracers evaluated so far for the determination of the BCM in vivo in humans will be discussed.
Keywords: Beta-cell mass, radiotracers, peptides, antibodies, nuclear medicine, imaging
Current Pharmaceutical Design
Title: Development of Radiotracers for the Determination of the Beta-Cell Mass In Vivo
Volume: 16 Issue: 14
Author(s): Maarten Brom, Karolina Andraojc, Wim J.G. Oyen, Otto C. Boerman and Martin Gotthardt
Affiliation:
Keywords: Beta-cell mass, radiotracers, peptides, antibodies, nuclear medicine, imaging
Abstract: The changes in beta-cell mass (BCM) during the course of diabetes are not yet well characterized. A non-invasive method to measure the BCM in vivo would allow us to study the BCM during the onset and progression of the diseases caused by beta-cell dysfunction. PET and SPECT imaging are attractive approaches to determine the BCM because of their high sensitivity and the possibility to quantitatively analyze the images. Several targets and their corresponding radiotracers have been examined for their ability to determine the BCM including radiolabeled antibodies, antibody fragments, peptides and small molecules. Although some of these tracers show promising results, there is still no reliable method to determine the beta-cell mass in vivo. In this review, the targets and the corresponding radiotracers evaluated so far for the determination of the BCM in vivo in humans will be discussed.
Export Options
About this article
Cite this article as:
Brom Maarten, Andraojc Karolina, J.G. Oyen Wim, C. Boerman Otto and Gotthardt Martin, Development of Radiotracers for the Determination of the Beta-Cell Mass In Vivo, Current Pharmaceutical Design 2010; 16 (14) . https://dx.doi.org/10.2174/138161210791164126
DOI https://dx.doi.org/10.2174/138161210791164126 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamins B1, B2, B3 and B9 – Occurrence, Biosynthesis Pathways and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry Imaging Amyloid Pathology in the Living Brain
Current Medical Imaging Fungal Bioactive Compounds in Pharmaceutical Research and Development
Current Bioactive Compounds Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Use of Benzodiazepines and Haloperidol Among Orthopedic Patients in Postoperative Delirium. A Systematic Review
Current Psychopharmacology A Case of Ischemic Stroke in Acute Promyelocytic Leukemia at Initial Presentation: Relevance of All-Trans Retinoic Acid Treatment
Cardiovascular & Hematological Disorders-Drug Targets Is Alpha-Synuclein Pathology a Target for Treatment of Neurodegenerative Disorders?
Current Alzheimer Research Isotyping the Human TOMM40 Variable-Length Polymorphism by Gene Amplification and Restriction Digest
Current Alzheimer Research Glia as a Turning Point in the Therapeutic Strategy of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Validating Immunotherapy in Alzheimer’s Disease: The EB101 Vaccine
Current Pharmaceutical Design TNF-α Inhibitors with Anti-Oxidative Stress Activity from Natural Products
Current Topics in Medicinal Chemistry Nanoemulsions for Improved Efficacy of Phytotherapeutics- A Patent Perspective
Recent Patents on Nanotechnology Selenium in the Therapy of Neurological Diseases. Where is it Going?
Current Neuropharmacology Evolution of Antipsychotic Intervention in the Schizophrenic Psychosis
Current Drug Targets Brain Inflammation, Cholesterol, and Glutamate as Interconnected Participants in the Pathology of Alzheimers Disease
Current Pharmaceutical Design Erythrocyte Associated Amyloid-β as Potential Biomarker to Diagnose Dementia
Current Alzheimer Research Editorial [Hot Topic: Drug Targets in Alzheimers Disease (Executive Editors: G. Munch and G. Stuchbury)]
Current Pharmaceutical Design Expression and Function of Organic Cation and Anion Transporters (SLC22 Family) in the CNS
Current Pharmaceutical Design Implication of Green Tea as a Possible Therapeutic Approach for Parkinson Disease
CNS & Neurological Disorders - Drug Targets Nutraceuticals in Psychiatric Practice
Recent Patents on CNS Drug Discovery (Discontinued)